Core Insights - Kineta, Inc. has resumed patient enrollment in the VISTA-101 Phase 1/2 clinical trial for KVA12123, a novel immunotherapy targeting cancer immune resistance, after a temporary suspension due to funding issues [1][10] - The company has enrolled 30 patients to date and anticipates full enrollment by the end of 2024 [1] - Initial results from the trial have shown promising outcomes, including partial responses and stable disease, with a favorable safety profile [2][3] Clinical Trial Details - KVA12123 has successfully cleared five of six monotherapy dose levels and two of four combination cohorts with Merck's KEYTRUDA® [2] - The trial has reported no dose-limiting toxicities or evidence of cytokine release syndrome at any dose level [2][3] - The completion of enrollment in the Phase 1 portion of the trial is considered a significant milestone for the development program [5] Strategic Partnerships - Kineta has entered into an exclusivity agreement with TuHURA Biosciences, receiving a $5 million nonrefundable payment to support the reinitiation of patient enrollment [4] - The agreement grants TuHURA exclusive rights to acquire Kineta's worldwide patents and related assets associated with KVA12123 [6] Company Overview - Kineta is a clinical-stage biotechnology company focused on developing next-generation immunotherapies for cancer treatment [8] - The company's pipeline includes KVA12123 and a preclinical monoclonal antibody targeting CD27, addressing major challenges in current cancer therapies [8][9]
Kineta Reopens Enrollment for the VISTA-101 Clinical Trial Evaluating KVA12123 in Patients with Advanced Solid Tumor Cancer